您的购物车当前为空
PDD00017273 是一种有效的放射增敏作用(二磷酸腺苷核糖)的水解酶 (PARG) 抑制剂,具有抗肿瘤或活性。PDD00017273 具有放射增敏作用,可用于研究上皮性卵巢。


为众多的药物研发团队赋能,
让新药发现更简单!
PDD00017273 是一种有效的放射增敏作用(二磷酸腺苷核糖)的水解酶 (PARG) 抑制剂,具有抗肿瘤或活性。PDD00017273 具有放射增敏作用,可用于研究上皮性卵巢。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 mg | ¥ 889 | 现货 | |
| 10 mg | ¥ 1,290 | 现货 | |
| 25 mg | ¥ 2,180 | 现货 | |
| 50 mg | ¥ 3,280 | 现货 | |
| 100 mg | ¥ 4,790 | 现货 | |
| 500 mg | ¥ 9,870 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 987 | 现货 |
| 产品描述 | PDD00017273 is a radiosensitizing PARG) inhibitor with antitumor or activity for the study of epithelial ovaries. |
| 靶点活性 | PARG:1.45 nM (Kd), PARG:26 nM |
| 体外活性 | PDD 00017273 is an effective inhibitor of PARG with an IC50 of 26 nM and a KD of 1.45 nM. At 10 μM, PDD 00017273 does not inhibit five common cytochrome P450 enzymes. At 30 μM, it moderately increases phosphorylated H2AX (γH2AX) intensity. Additionally, PDD 00017273 reduces NAD/H through PARG inhibition after DNA damage. The compound inhibits ZR-75-1 cells carrying wild-type BRCA1 and BRCA2 and exhibits weaker activity against MDA-MB-436 cells carrying the 5396 + 1G>A mutation in BRCA1[2].At 0.3 μM, PDD 00017273 inhibits the degradation of PAR polymers in MCF7 cells. It also reduces the viability of BRCA1, BRCA2, PALB2, FAM175A, and BARD1-depleted cells. PDD 00017273 halts replication forks and induces DNA damage requiring homologous recombination (HR) for repair[1]. |
| 分子量 | 514.62 |
| 分子式 | C23H26N6O4S2 |
| CAS No. | 1945950-21-9 |
| Smiles | Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1 |
| 密度 | 1.52 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 40.83 mg/mL (79.34 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.89 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多